Premium
Efficacy and safety of high infusion rate IVIG in CIDP
Author(s) -
Jiang Yue,
Mendoza Meg,
Sarpong Evelyn,
Mannan Shabber,
Ng Eduardo,
Katzberg Hans,
Bril Vera,
Barnett Carolina
Publication year - 2020
Publication title -
muscle and nerve
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.025
H-Index - 145
eISSN - 1097-4598
pISSN - 0148-639X
DOI - 10.1002/mus.27044
Subject(s) - medicine , polyradiculoneuropathy , adverse effect , anesthesia , recovery rate , continuous infusion , guillain barre syndrome , pediatrics , chemistry , chromatography
Background We aimed to determine the safety and tolerance of higher rates of infusion of intravenous immunoglobulin (IVIG) in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Methods Patients began infusions with 10% IVIG at the standard rate of 0.08 mL/kg/min. If tolerated, infusion rates were incrementally increased to 0.14 mL/kg/min. We considered the frequency of infusions with adverse events (AEs) as the primary outcome. Results Nineteen of 25 patients safely tolerated the maximum rate of 0.14 mL/kg/min. We observed 25 treatment‐related AEs (TAEs) over 13 infusions at standard or transitional rates, across seven patients. We observed no TAEs associated with the maximum infusion rate. Conclusions We found that 10% IVIG can be safely administered at a high infusion rate (0.14 ml/kg/min) in most CIDP patients, reducing the treatment time and burden on healthcare resources.